Private Advisor Group’s AN2 Therapeutics ANTX Stock Holding History

Private Advisor Group’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,500	Closed	-$42.8K	–	2529
2026 Q1	$42.8K	Sell	12,500 -10,000	-44%	-$20.6K	﹤0.01%	2588
2025 Q4	$25.6K	Hold	22,500	–	–	﹤0.01%	2551
2025 Q3	$28.6K	Hold	22,500	–	–	﹤0.01%	2483
2025 Q2	$23.9K	Hold	22,500	–	–	﹤0.01%	2390
2025 Q1	$30.6K	Hold	22,500	–	–	﹤0.01%	2254
2024 Q4	$31.1K	Hold	22,500	–	–	﹤0.01%	2233
2024 Q3	$24.1K	Hold	22,500	–	–	﹤0.01%	2368
2024 Q2	$48.4K	Hold	22,500	–	–	﹤0.01%	2277
2024 Q1	$73.1K	Buy	+22,500	New	+$245K	﹤0.01%	2226
2023 Q3	–	Sell	-67,500	Closed	-$574K	–	2294
2023 Q2	$574K	Buy	67,500 +45,492	+207%	+$327K	0.01%	1308
2023 Q1	$217K	Buy	22,008 +11,000	+100%	+$122K	﹤0.01%	1755
2022 Q4	$105	Buy	+11,008	New	+$147K	﹤0.01%	1577
2022 Q3	–	Sell	-11,001	Closed	-$165K	–	1923
2022 Q2	$165K	Buy	+11,001	New	+$146K	﹤0.01%	1882

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Private Advisor Group's ANTX Position: Q2 2026 in Review

Private Advisor Group sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 12,500 shares — an estimated $42.8K sold.

Private Advisor Group first reported a position in ANTX in Q2 2022 and held it in 13 quarters. The position peaked at $574K in Q2 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Private Advisor Group reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
Private Advisor Group sold 12,500 AN2 Therapeutics shares in Q2 2026, an estimated $42.8K.
Private Advisor Group first reported a position in AN2 Therapeutics in Q2 2022 and held it in 13 quarters.
Private Advisor Group's AN2 Therapeutics position peaked at $574K in Q2 2023.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.